lutetium has been researched along with lead radioisotopes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bednarz, B; Lee, D; Li, M; Schultz, MK | 1 |
| Chuvilin, DY; Deev, SM; Egorova, BV; Golovachenko, VA; Kaprin, AD; Kokov, KV; Lebedenko, EN; Nemtsova, ER; Pankratov, AA; Plyutinskaya, AD; Proshkina, GM; Shegai, PV; Shul'ga, AA; Vorontsova, MS | 1 |
| Donnelly, PS; Morgan, KA; Noor, A; Rudd, SE | 1 |
1 review(s) available for lutetium and lead radioisotopes
| Article | Year |
|---|---|
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
Topics: Copper Radioisotopes; Humans; Lead Radioisotopes; Lutetium; Male; Nuclear Medicine; Radiopharmaceuticals | 2023 |
2 other study(ies) available for lutetium and lead radioisotopes
| Article | Year |
|---|---|
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes | 2018 |
Specific Cytotoxicity of Targeted
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Immunotoxins; Lead Radioisotopes; Lutetium; MCF-7 Cells; Molecular Targeted Therapy; Radioisotopes; Radiopharmaceuticals; Substrate Specificity | 2021 |